Mounjaro and breastfeeding: what the FDA label §8.2 Lactation actually says

The Mounjaro FDA label Section 8.2 Lactation reports that, in a single-dose clinical lactation study in 11 healthy lactating adult females, tirzepatide was undetectable in 164 of 171 breast-milk samples; the cumulative detected amount was less than 0.02% of the maternal administered dose^[1]. There are no available data on the effects on the breastfed infant or on milk production. Tirzepatide elimination half-life is approximately 5 days per Section 12.3^[1]. The decision to continue, pause, or start Mounjaro while breastfeeding belongs with your prescriber.

At a glance

• FDA Section 8.2 Lactation (Mounjaro): tirzepatide either undetectable or very low in breast milk in a single-dose human pharmacokinetic study (n=11)^[1].
• Cumulative breast-milk exposure: less than 0.02% of the maternal administered dose^[1].
• Effect on infant or on milk supply: no available data per the FDA label^[1].
• Half-life (FDA Section 12.3): approximately 5 days; clearance 0.061 L/h^[1].
• Washout convention: the standard pharmacokinetic threshold of five half-lives is roughly 25 days for tirzepatide (label does not specify a lactation-specific washout)^[1].
• Class-effect human milk data (semaglutide): Diab 2024 (Nutrients) reported very low transfer of subcutaneous semaglutide into human milk^[2].
• Class-effect systematic review: Muller 2023 (Frontiers in Endocrinology) — human lactation data for GLP-1s remain sparse; decisions must be individualized^[3].

What the Mounjaro FDA label Section 8.2 Lactation says (verbatim)

From the Mounjaro prescribing information, DailyMed SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0, Section 8.2 Lactation, Risk Summary^[1]:

In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose (see Data). There are no available data on the effects of tirzepatide on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for MOUNJARO and any potential adverse effects on the breastfed infant from MOUNJARO or from the underlying maternal condition.

And the Section 8.2 Data subsection^[1]:

Following subcutaneous administration of a single 5 mg dose to 11 healthy lactating adult females, the concentration of tirzepatide in breast milk was found to be undetectable (limit of detection in breast milk 4 ng/mL) in 164/171 samples assayed. The cumulative amount of tirzepatide detected in the remaining 7 breast milk samples over the 28-day sampling window was equivalent to less than 0.02% of the maternal administered dose, with the last measurable concentrations occurring 5 days post-dose. The AUC of tirzepatide in breast milk could not be calculated, due to insufficient quantifiable concentrations.

Two things to read carefully. First, this is a single-dose study — it tells us what one 5 mg dose looks like in milk over 28 days; it does not tell us what steady-state once-weekly dosing at 15 mg looks like over months. Second, the label does not say Mounjaro is safe during breastfeeding. It reports the milk-transfer pharmacokinetic data, acknowledges the absence of infant outcome data, and defers the clinical weighing to the prescriber.

What Section 12.3 Pharmacokinetics tells us about washout

The Mounjaro Section 12.3 reports the apparent population mean clearance of tirzepatide is 0.061 L/h with an elimination half-life of approximately 5 days, enabling once-weekly dosing^[1]. The label Overdosage section adds that “a period of observation and treatment for these symptoms may be necessary, taking into account the half-life of tirzepatide of approximately 5 days”^[1].

The standard pharmacokinetic convention for “fully out of the body” is about five half-lives, which puts tirzepatide washout at roughly 25 days. That is a rule of thumb, not a regulatory deadline. For deeper background on what “in your system” means for every GLP-1, see our companion explainer: How long does a GLP-1 stay in your system — semaglutide, tirzepatide, and orforglipron.

The Mounjaro Section 8.2 label does not specify a lactation washout interval (unlike the pre-conception language in some other labels — for context see our GLP-1s in pregnancy, PCOS, and fertility guide). Whether any washout is appropriate before resuming or starting breastfeeding is a prescriber-level individualized decision.

What class-effect lactation data exists for the GLP-1s

Tirzepatide is one of four GLP-1 receptor agonists with meaningful published human-milk pharmacokinetic data; the others are semaglutide (the molecule in Wegovy and Ozempic), liraglutide (in Saxenda), and exenatide.

Semaglutide (Wegovy / Ozempic)

Diab and colleagues (2024, Nutrients, PMID 39275201) directly measured subcutaneous semaglutide transfer into human milk and reported the relative infant dose was very low, consistent with the low oral bioavailability of large peptide drugs and the gut-degradation argument that has long been applied to insulin and GLP-1s in lactation^[2]. The authors framed the findings as supportive of low expected systemic exposure in the breastfed infant but deferred clinical decisions to the prescriber.

Liraglutide and exenatide

Published human-milk data for liraglutide and exenatide are even sparser. The Muller 2023 systematic review^[3] collated the available evidence and concluded that human lactation data for the GLP-1 class as a whole remain insufficient to draw broad safety conclusions, and that decisions should be individualized between the patient and prescriber.

Why the “peptide drugs probably don't reach the infant” argument has limits

A common informal argument is: GLP-1s are large peptides; oral bioavailability is near zero; even if a peptide reaches breast milk, it would be degraded in the infant's gastrointestinal tract before systemic absorption. That argument is biologically reasonable and is part of why regulators have not contraindicated GLP-1s in lactation — but it is not the same as empirical evidence of infant safety. It does not address potential local effects on the infant gut, on milk composition, on maternal milk supply via prolactin or appetite-mediated caloric intake, or on long-term infant growth. None of those have been studied at scale.

LactMed status for tirzepatide

LactMed (the NIH Drugs and Lactation Database, NBK501922) is the canonical clinical reference for lactation pharmacology^[4]. The tirzepatide LactMed entry reflects the same single-dose clinical lactation data summarized in the Mounjaro FDA label Section 8.2 and notes there is no information on long-term effects in breastfed infants. LactMed's practical recommendation pattern for drugs with limited human lactation data is to weigh the clinical need, consider the infant's age and prematurity (older, term infants tolerate broader pharmacology than neonates), and individualize with the prescriber.

Why human lactation studies haven't been done at scale

Lactating parents are routinely excluded from premarket drug trials because infants cannot consent to drug exposure. Lactation data therefore lag pregnancy data, which already lag adult efficacy data. The Mounjaro n=11 single-dose study is actually more empirical lactation data than most newly approved drugs have. The EASO 2025 Position Statement on women with obesity across the reproductive life (Filippi-Arriaga 2025 PMID 40544836)^[5] notes that postpartum and breastfeeding obesity care is a chronically under-evidenced field and calls for prospective registries — the same gap noted by Muller 2023^[3].

Practical questions to bring to your prescriber

If you are breastfeeding and considering Mounjaro — or are already on Mounjaro and have started or are continuing breastfeeding — these are reasonable conversation prompts. They are questions to ask, not answers we are providing.

• What is the clinical indication (T2D management vs weight management) and how urgent is starting Mounjaro now versus waiting until weaning?
• Is there a non-GLP-1 alternative for my indication that would be more compatible with lactation?
• For T2D specifically: would an insulin-based or metformin-based regimen be reasonable during the breastfeeding window?
• Given the ~5-day half-life, would a temporary pause make sense for any planned procedure or infant exposure window?
• What infant monitoring would you suggest if I continue — feeding behavior, growth trajectory, hydration?
• Is my infant's age and term status relevant to your weighing of risks and benefits?
• Should we involve an IBCLC to monitor milk supply if I start or restart Mounjaro?

How this fits into the broader Mounjaro safety picture

For broader Mounjaro context that may inform a lactation-period conversation: our Mounjaro and Zepbound birth control warning breaks down the FDA-mandated 4-week backup contraception window after starting and after each dose escalation (a reproductive-health detail unique to tirzepatide among injectable GLP-1s), and our GLP-1s in pregnancy, PCOS, and fertility guide covers the verified pre-conception language in each FDA label. For the molecule itself, see our Mounjaro drug page.

Bottom line

The Mounjaro FDA label Section 8.2 Lactation reports that tirzepatide transfers into human milk at very low or undetectable concentrations after a single 5 mg dose, and acknowledges that there are no available data on effects on the breastfed infant or on milk production^[1]. The elimination half-life is approximately 5 days^[1]. Class-effect data for semaglutide^[2] and the Muller 2023 systematic review^[3] point in the same direction — low expected exposure, sparse infant-outcome data, decision belongs with the prescriber. We do not tell you whether to take Mounjaro while breastfeeding. We tell you what the label says and what the published evidence shows, and we ask you to bring those facts to the clinician who knows your indication, your infant, and your full medical picture.

Editorial note. All clinical claims in this article were verified live on 2026-05-24. The Mounjaro Section 8.2 and 12.3 quotes were taken directly from the DailyMed-hosted FDA prescribing information (SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0). The three PubMed-indexed class-effect references (Diab 2024 PMID 39275201; Muller 2023 PMID 37881498; Filippi-Arriaga 2025 PMID 40544836) were verified via the NCBI esummary API on the publication date. LactMed (NBK501922) was verified by HTTP 200 from the canonical NCBI Bookshelf URL.